Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Vivoryon Therapeutics  /  Probiodrug 2018

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel VIVORYON THERAPEUTICS N.V. AEX:VVY.NL, NL00150002Q7

  • 0,720 23 apr 2024 17:35
  • +0,150 (+26,32%) Dagrange 0,613 - 0,825
  • 2.581.230 Gem. (3M) 632,4K

Probiodrug 2018

1.897 Posts
Pagina: «« 1 ... 54 55 56 57 58 ... 95 »» | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 6 juli 2018 22:17
    quote:

    Gala-diner schreef op 6 juli 2018 22:09:

    [...]Je begrijpt het spel niet, binnenkort zal het zelfs voor jou duidelijk worden.
    Dan zien wij jou op dit forum niet meer en heb je een mega-kans gemist...
    Leg jij 'het spel' even uit aan al die newbies die hier hun geld kwijtraken....!
  4. forum rang 7 Kaviaar 7 juli 2018 13:24
    quote:

    DeZwarteRidder schreef op 7 juli 2018 09:26:

    [...]
    Dus je wilt 'het spel' niet uitleggen aan de newbies die hier grote verliezen lijden...??

    Wat ben je toch een goede zak DZR. Je wilt iedereen redden....zo lijkt het. Bij Pharming zat je er maar mijlenver naast.
    Als je niet in een aandeel handelt, post dan geen onzin op zo'n forum.

    Je kan beter met je hobbelpaard de wijde wereld intrekken en monnik worden of iets dergelijks.
  5. forum rang 7 Kaviaar 7 juli 2018 13:30
    Het Duitse Probiodrug, dat genoteerd is aan de beurs in Amsterdam, werkt aan geneesmiddelen tegen de ziekte van Alzheimer. Daarbij maakt het gebruik van technologie die ontwikkeld is door het Nederlandse Crossbeta.

    www.belegger.nl/Beursnieuws/ANP-05121...

    Crossbeta is absoluut geen flutbedrijf! Goed doorlezen is mijn advies.

    www.jaarverslagenrvo.nl/jaarjournaal/...
  9. [verwijderd] 7 juli 2018 15:32
    quote:

    DeZwarteRidder schreef op 7 juli 2018 09:26:

    [...]
    Dus je wilt 'het spel' niet uitleggen aan de newbies die hier grote verliezen lijden...??
    Hou toch op met dat gezwam over newbies die hun geld kwijtraken zwartmans.
    We weten heus wel wat de risico's zijn met dit soort fondsen. Bovendien leer je daarvan
  13. Omegaplan 9 juli 2018 09:34
    Crossbeta goes virtual as of July 1st, 2018. This implies that we will continue to exist, but without our team and without our own lab facilities.

    Our oligomer business will be transferred to another party (name to be disclosed at a later stage) and as soon as we have completed the funding for our Alzheimer gene therapy program this will be continued at DegenRx, a Crossbeta spinout.

    We hope to stay in touch and please feel free to contact me if you have any questions.

    4-juni jl. persbericht ontvangen.
  14. Gala-diner 9 juli 2018 16:21
    quote:

    Omegaplan schreef op 9 juli 2018 09:34:

    Crossbeta goes virtual as of July 1st, 2018. This implies that we will continue to exist, but without our team and without our own lab facilities.

    Our oligomer business will be transferred to another party (name to be disclosed at a later stage) and as soon as we have completed the funding for our Alzheimer gene therapy program this will be continued at DegenRx, a Crossbeta spinout.

    We hope to stay in touch and please feel free to contact me if you have any questions.

    4-juni jl. persbericht ontvangen.

    markets.businessinsider.com/news/stoc...

    ImmunoPrecise to acquire Crossbeta Research BV

    PRESS RELEASE PR Newswire
    Dec. 22, 2017, 03:22 PM

    VICTORIA, BC, Dec. 22, 2017 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company") (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with Crossbeta Biosciences B.V. ("Crossbeta") whereby the Company has agreed to acquire all of the issued and outstanding shares of Crossbeta (the "Transaction").

    The Transaction continues to realize on the Board's commitment to grow globally through strategic acquisitions. It allows IPA to build a pipeline of antibodies with application in biomarker/diagnostic assays and as therapeutics and thereby significantly extends its ambition of becoming a single source provider of services across the full antibody discovery value chain (antigen design, hit generation, lead selection, lead optimization and lead characterization) and to offer the full spectrum of antibody production methodologies (library based technologies, hybridoma methods, transgenic animal based platforms and single B cell based technology). Furthermore, the acquisition enhances the Company's source of and capacity for developing unique antigens for generating and selecting antibodies.

    Crossbeta

    Crossbeta is a privately held company based in the Netherlands with a proprietary technology for efficient oligomer-based drug discovery, with applications in Alzheimer's, Parkinson's, ALS and Huntington's disease. Crossbeta's technology allows the generation of well-defined stable, pathobiologically functional, oligomers. Crossbeta's oligomers allow fast, de-risked drug candidate screening and the generation of antibodies with high affinity as well as high specificity. The capabilities of Crossbeta's technology have already yielded multiple antibodies with biomarker/diagnostic and therapeutic potential for Alzheimer's and Parkinson's disease.

    Crossbeta offers its proprietary technology for strategic collaborative partnerships aimed at developing new oligomer targets and related screening assays and for therapeutic and diagnostic/biomarker assay development programs.

    The Transaction brings in important intellectual property and technology in connection with the treatment of age-related diseases to the Company.

    Terms of Transaction with Crossbeta

    Under the binding letter of intent, the Company and Crossbeta have agreed to negotiate a definitive agreement (the "Definitive Agreement") whereby the Company will acquire all of the issued and outstanding shares of Crossbeta for €8,500,000 (CAD$12,835,000) (the "Purchase Price") by either (A) the issuance of common shares of the Company on closing of the Transaction, or (B) the issuance of convertible notes that bear interest at a rate of 6% per annum (the "Notes") on closing of the Transaction. The Notes will be convertible, at the option of the holder, into cash or shares of the Company in increments of 25% of their total value at six, eighteen, thirty and thirty-six months after the date of closing. Notwithstanding the foregoing, the Company to repay the notes with cash at any time.

    The letter of intent also sets forth the Company's commitment to fund Crossbeta, after being acquired by the Company, for a total of €15,000,000 (CAD$22,650,000) as follows: (A) €800,000 (CAD$1,208,000) on closing of the Transaction, (B) €5,000,000 (CAD$7,550,000) upon commencement of preclinical trials, and (C) €9,200,000 (CAD$13,892,000) upon commencement of human clinical trials. The Company will also commit up to €800,000 (CAD$1,208,000) for gene therapy for the shark antibody
    The CEO of Crossbeta will also enter into a three year management contract, which will include non-solicitation and non-competition clauses. The Company has also agreed to appoint one of the principal shareholders of Crossbeta to its board of directors.

    The parties will be entitled to carry out due diligence of each other until January 15, 2018. Upon the parties completing due diligence to their reasonable satisfaction, the parties will enter into the Definitive Agreement setting forth the terms and conditions of the Transaction by January 30, 2018. Completion of any transaction with Crossbeta is subject to a number of conditions, including but not limited to, completion of due diligence, negotiation of definitive agreements in respect of such a transaction, the availability of financing on terms acceptable to the Company, and receipt of any required regulatory and shareholder approvals. A transaction cannot be completed until these conditions are satisfied, and there can be no assurance that a transaction will be completed at all.

  15. [verwijderd] 10 juli 2018 16:19
    Heeft op zich toch geen effect op onderstaande samenwerking?

    HALLE (SAALE), Germany, UTRECHT, The Netherlands, 5 December 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), and the Dutch biotech company Crossbeta Biosciences B.V., announced today that they have extended their strategic partnership regarding the use of Crossbeta's proprietary technology for biomarker development, in support of Probiodrug's clinical program in Alzheimer's disease.

    The companies first established the partnership in 2016. Since then, the very challenging program, focused on oligomer-specific biomarker assays and diagnostics, has made excellent progress and has successfully met all critical milestones. By leveraging the pivotal role of protein oligomers in AD pathology, the partners are aiming to develop a truly disease-specific AD biomarker and diagnostic with prognostic clinical value.

    Inge Lues, Chief Development Officer of Probiodrug, commented: "Our partnership with Crossbeta has granted us access to a truly unique technology which has proven to be crucially important for the development of high-quality biomarker assays, with adequate sensitivity and specificity to support and further the clinical program of Probiodrug's QC inhibitor PQ912."

    Guus Scheefhals, Chief Executive Officer of Crossbeta, added: "We are very pleased about the extension of our partnership with Probiodrug. It is an honor being able to contribute to Probiodrug's exciting and encouraging therapeutic program in AD with our proprietary technology. In case of successful achievement of our goals, not only many other scientists and companies will benefit from the availability of this novel, prognostic biomarker and diagnostic, but it will bring urgently needed benefit to AD patients."
  16. Gala-diner 10 juli 2018 22:28
    quote:

    Peermanpaapskop schreef op 10 juli 2018 16:19:

    Heeft op zich toch geen effect op onderstaande samenwerking?

    HALLE (SAALE), Germany, UTRECHT, The Netherlands, 5 December 2017 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), and the Dutch biotech company Crossbeta Biosciences B.V., announced today that they have extended their strategic partnership regarding the use of Crossbeta's proprietary technology for biomarker development, in support of Probiodrug's clinical program in Alzheimer's disease.

    The companies first established the partnership in 2016. Since then, the very challenging program, focused on oligomer-specific biomarker assays and diagnostics, has made excellent progress and has successfully met all critical milestones. By leveraging the pivotal role of protein oligomers in AD pathology, the partners are aiming to develop a truly disease-specific AD biomarker and diagnostic with prognostic clinical value.

    Inge Lues, Chief Development Officer of Probiodrug, commented: "Our partnership with Crossbeta has granted us access to a truly unique technology which has proven to be crucially important for the development of high-quality biomarker assays, with adequate sensitivity and specificity to support and further the clinical program of Probiodrug's QC inhibitor PQ912."

    Guus Scheefhals, Chief Executive Officer of Crossbeta, added: "We are very pleased about the extension of our partnership with Probiodrug. It is an honor being able to contribute to Probiodrug's exciting and encouraging therapeutic program in AD with our proprietary technology. In case of successful achievement of our goals, not only many other scientists and companies will benefit from the availability of this novel, prognostic biomarker and diagnostic, but it will bring urgently needed benefit to AD patients."
    Nee natuurlijk niet, als dat wel zo zou zijn dan was dat al lang door Probiodrug naar buiten gebracht.
1.897 Posts
Pagina: «« 1 ... 54 55 56 57 58 ... 95 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

VIVORYON THERAPEUTICS N.V. Nieuws

  1. 16 apr Vivoryon publiceert cijfers 2023 eind april
  2. 26 mrt Warburgs vreselijke Vivoryon-misser
  3. 19 mrt Christiansen weer kleiner in Vivoryon 1
  4. 15 mrt Deel van commissarissen Vivoryon stapt op 1
  5. 09 mrt UBS kleiner in Vivoryon
  6. 06 mrt Aandeelhouder GS&P zegt vertrouwen in Vivoryon op
  7. 05 mrt Jefferies verlaagt koersdoel Vivoryon met 96% 2
  8. 04 mrt Koers Vivoryon implodeert 3
  9. 04 mrt Jefferies: oorwassing Vivoryon dreigt na mislukken alzheimerstudie
  10. 04 mrt AEX gaat nipt hogere opening tegemoet - voorspelt S&P 500 uitslag verkiezingen VS? 2

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!